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short term, there were minimal differences in liver toxicity favoring CyBu over BuCy, significant only for
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Abstract
Busulfan and cyclophosphamide (BuCy) is a frequently used myeloablative conditioning regimen for allogeneic hematopoietic
cell transplantation (allo-HCT). Theoretical considerations and pharmacological data indicate that application of busulfan prior to
subsequent cyclophosphamide (BuCy) may trigger liver toxicity. Reversing the order of application to cyclophosphamide-
busulfan (CyBu) might be preferable, a hypothesis supported by animal data and retrospective studies. We performed a pro-
spective randomized trial to determine impact of order of application of Bu and Cy before allo-HCT in 70 patients with
hematological malignancy, 33 patients received BuCy and 37 CyBu for conditioning. In the short term, there were minimal
differences in liver toxicity favoring CyBu over BuCy, significant only for alanine amino transferase at day 30 (p = 0.03). With
longer follow-up at 4 years, non-relapse mortality (6% versus 27%, p = 0.05) was lower and survival (63% versus 43%, p = 0.06)
was higher with CyBu compared to BuCy. Other outcomes, such as engraftment (p = 0.21), acute and chronic graft-versus-host
disease (p = 0.40; 0.36), and relapse (p = 0.79), were similar in both groups. We prospectively show evidence that the order of
application of Cy and Bu in myeloablative conditioning in allo-HCT patients has impact on outcome.
Keywords Busulfan . Conditioning regimen . Cyclophosphamide . Hematopoietic cell transplantation . Liver toxicity
Claire Seydoux and Michael Medinger contributed equally to this work.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00277-020-04312-y) contains supplementary
material, which is available to authorized users.
* Michael Medinger
michael.medinger@usb.ch
* Jakob R. Passweg
jakob.passweg@usb.ch
1 Divisions of Hematology and Internal Medicine, Department of
Medicine, University Hospital of Basel, Petersgraben 4,
CH-4031 Basel, Switzerland
2 Division of Hematology, Bone Marrow Transplant Unit, University
Hospital of Geneva and Faculty of Medicine, University of Geneva,
Geneva, Switzerland
3 Department of Medical Oncology and Hematology, Stem-/Immune-
cell-transplant Unit, University Hospital of Zurich,
Zurich, Switzerland
4 Department Women, Children and Adolescent, Unit of Oncology
and Hematology Pediatric, University Hospital of Geneva,
Geneva, Switzerland
5 Cansearch Research Laboratory, Faculty of Medicine, University of
Geneva, Geneva, Switzerland
6 Clinical Trials Unit, Department of Clinical Research, Basel
University, Basel, Switzerland
7 Division of Oncology, Hematology and Transfusion Medicine,
Kantonsspital Aarau, Aarau, Switzerland
https://doi.org/10.1007/s00277-020-04312-y
/ Published online: 23 October 2020
Annals of Hematology (2021) 100:209–216
Introduction
The combination of busulfan and cyclophosphamide (BuCy) is
a frequently used established myeloablative conditioning regi-
men before allogeneic cell transplantation (allo-HCT).
Antileukemic effects and myeloablative properties of this reg-
imen in patients with hematological malignancies have been
confirmed in multiple studies [1–4]. Interactions between bu-
sulfan (Bu) and cyclophosphamide (Cy) are well described [5,
6]; studies have shown that Bu affects the hepatic metabolism
of Cy and may therefore increase liver toxicity when given in
this order [7, 8]. The pathophysiology behind this interference
is possibly a decrease in levels of glutathione, which is a major
player in the breakdown of metabolites of Cy in the hepatocyte
[9, 10]. Cy-induced toxicity has been associated with non-
relapse mortality (NRM) and decreased survival in clinical
studies [11]. The most feared hepatic complication is veno-
occlusive disease/sinusoidal obstruction syndrome (VOD/
SOS) described with the BuCy regimen [12–15]. As suspected
in some retrospective clinical and animal studies, reversing the
order of application of BuCy to CyBu may decrease liver tox-
icity without loss in antileukemic activity [6, 16–19]. In earlier
years, when only oral Bu was available, the order of BuCy was
preferred because of the emetogenic potential of Cy precluding
administration of correct doses of Bu. With the introduction of
intravenous Bu, associated with reduced liver complications
and mortality [7], these considerations influencing the order
of application no longer apply.
With this prospective randomized controlled trial (RCT),
we aimed to test the impact of the order of application of
BuCy versus CyBu prior to allo-HCT in patients with hema-
tological malignancies.
Patients and methods
Study cohort and design
This is a prospective multicenter (University Hospitals Basel,
Zurich, and Geneva) open label 1:1 RCT, comparing the order
of application of busulfan followed by cyclophosphamide
(BuCy, standard group) versus cyclophosphamide followed
by busulfan (CyBu, experimental group) as myeloablative
conditioning regimen prior to allo-HCT done between 2013
and 2017. The study was approved by the local ethics com-
mittee (EKNZ EKBB179/12), by Swissmedic (2012DR4164)
and was registered with ClinicalTrials.gov as NCT01779882.
Randomization was centrally at the Clinical Trial Unit (CTU)
of the Basel University Hospital.
The primary endpoint, as defined in the protocol, was liver
toxicity of BuCy versus CyBu at day 30 after allo-HCT, de-
fined as abnormality in the levels of bilirubin, aspartate amino
transferase (ASAT), alanine amino transferase (ALAT),
gamma glutamyl transpeptidase (GGT), or alkaline phospha-
tase (AP). In addition, we used the NCI Common
Terminology Criteria for Adverse Events (CTCAE version
4.0) grading of hepatic toxicity [20].
Secondary endpoints were the incidence and severity of
VOD, incidence of other organ toxicity before day 30 and at
day 100, incidence and severity of acute and chronic GvHD,
and overall survival, relapse, and non-relapse mortality inci-
dence at day 100 and at long-term follow-up.
Consenting and included patients were adults planned for
myeloablative conditioning allo-HCT to treat acute myeloid
leukemia (AML), chronic myeloid leukemia (CML), acute
lymphoblastic leukemia (ALL), and myelodysplastic syn-
drome (MDS) or myeloproliferative neoplasm (MPN). They
had an HLA-identical sibling or an allele (10/10) HLA-
matched unrelated donor. Patients with preexisting active hep-
atitis or abnormal pretransplant liver function tests within 2
weeks prior to starting conditioning, such as bilirubin > 3 ×
upper limit of normal (ULN) or ASAT/ALAT > 5 × ULN,
were excluded.
The inclusion goal was set at 72 patients (36 patients in
each arm) to ensure 65 evaluable patients considering a
drop-out rate of 10%, permitting a difference of 35% in detec-
tion of any abnormal liver values between the two groups on
days 30 and 100. These assumptions, and hence the accrual
goal, were derived from a previous retrospective study com-
paring CyBu with BuCy [17].
Patient baseline characteristics, such as sex, age, type, and
stage of disease, EBMT risk score, hematopoietic cell
transplantation-specific comorbidity index (HCT-CI) (Sorror),
Karnofsky performance score (KPS), viral serology, specifical-
ly hepatitis A, B, and C (HAV, HBV, HCV), cytomegalovirus
(CMV) and Ebstein-Barr-virus (EBV), prior autologous or
allo-HCT, and transplant characteristics including donor type,
sex, age and viral serology, stem cell source, and type of GvHD
prophylaxis were recorded.
Liver function tests were measured on the day of enroll-
ment and on days 0, 10, 20, 30, and 100, measuring levels of
bilirubin, ASAT, ALAT, GGT, and AP. Outcomes, including
time to neutrophil engraftment (defined as the first of 3 con-
secutive days of an absolute neutrophil count exceeding 0.5 ×
109/L), cumulative incidence of VOD, aGvHD, and cGvHD,
and grade and treatment, were measured. Survival was de-
fined as time from transplantation to death or last follow-up,
relapse was defined as hematologic relapse after allo-HCT,
and NRM was death without prior relapse.
Definitions
VODwas defined using the modified Seattle criteria [21] with
the occurrence of two of the following events within 20 days
of transplantation: hyperbilirubinemia (total serum bilirubin >
34.2 μmol/L (2 mg/dL)), hepatomegaly or right upper
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quadrant pain of liver origin, and sudden weight gain (> 2% of
baseline body weight) because of fluid accumulation.
Acute and chronic GvHD were diagnosed clinically and
confirmed histologically when possible. Grading and staging
used consensus classifications for acute and chronic GvHD
[22, 23]. Acute GvHD was defined as clinically relevant with
grade ≥ II.
Treatment
The standard group received the regular conditioning regi-
men: i.v. Bu (0.8 mg/kg every 6 h, as a 2-h infusion in NaCl
0.9% for a final concentration of 0.5 mg/mL; total 16 doses)
from days − 8 to − 4, followed by i.v. Cy (60 mg/kg in 5%
glucose) on days − 3 and − 2. Busulfan was started on the
evening of day − 8 such that the last dose was given at a time
interval of at least 24 h before the first cyclophosphamide dose
[8]. The experimental group received i.v. Cy on days − 8 and
− 7, and i.v. Bu from days − 5 to − 2, in the same doses but in
reversed order (supplementary file study protocol).
Busulfan pharmacokinetic dose adjustment was performed
from the fifth dose onward to achieve a target Css from 800 to
1000 ng/mL according to the centers’ guidelines [24]. VOD
prophylaxis consisted of intravenous heparin 5000 IU/24 h
and ursodeoxycholic acid 250 mg po 3 times daily in two of
the centers; one center (7 patients included) did not use VOD
prophylaxis. Patients with proven or highly probable VOD
were treated with defibrotide i.v. 6.25 mg/kg every 6 h until
resolution.
GvHD prophylaxis consisted of cyclosporine A (CsA) (3
mg/kg bw/day i.v.; starting day − 3 over 6 h adjusted to blood
trough levels targeting 150-200 μg/L) and methotrexate
(MTX) (15 mg/m2 i.v. day + 1; 10 mg/m2 day + 3 and day
+ 6). In addition, for HCT from unrelated donors and in one
center for matched related donors ≥ 40 years [25], ATG (n =
45) or alemtuzumab (n = 3) was used (Table 1). CsA was
tapered and discontinued 6 months post-transplant.
Supportive care was as per institutional guidelines and in-
cluded trimethoprim/sulfamethoxazole, fluconazole, and
valacyclovir. Lorazepam was given before Bu to reduce cen-
tral nervous system adverse reactions.
Statistical analysis
Data are reported as mean or median with standard deviation
(SD) or with interquartile range (IQR) as appropriate.
Differences among groups were analyzed using Chi-square
or Fisher’s exact test for categorical variables, and Student’s
t orMann-WhitneyU test for continuous variables, depending
on data distributions. Variables significantly associated with
outcome in univariate analysis were included in multivariate
Cox proportional hazards regression models. All p values
were two-sided and statistical significance was determined
Table 1 Patient, disease, and transplant characteristics
CyBu n = 37 BuCy n = 33 p value
Age (median, years; range) 47 (21-62) 46 (20-65) 0.49
Gender (male, %) 25 (68) 15 (46) 0.06
Donor/recipient gender
Female/male (n, %) 9 (24) 5 (15) 0.26
Other (n, %) 28 (76) 28 (85)
Disease
AML (n, %) 28 (76) 24 (73) 0.70
MDS/MPN (n, %) 7 (19) 7 (21)
CML (n, %) 2 (5) 1 (3)
ALL (n, %) 0 1 (3)
Prior HCT
Allogenic (n, %) 1 (3) 1 (3) 0.94
Autologous (n, %) 2 (5) 5 (15) 0.18
Disease status at HCT
CR or chronic phase 1 (n, %) 27 (73) 22 (67) 0.47
2.CR or never treated (n, %) 4 (11) 7 (21)
No CR (n, %) 6 (16) 4 (12)
Stem cell source
Peripheral blood (n, %) 37 (100) 31 ( 94) 0.13
Bone marrow (n, %) 0 (0) 2 (6)
Donor
HLA-identical sibling (n, %) 19 (51) 15 (46) 0.62
HLA-matched unrelated (n, %) 18 (49) 18 (54)
Donor age (median, years; range) 43 (20-68) 40 (20-61) 0.23
Donor/recipient CMV status 0.23
Neg/pos (n, %) 2 (5) 7 (21)
Other (n, %) 35 (95) 26 (79)
GvHD prophylaxis
ATG or T-depletion (n, %) 27 (73) 21 (64) 0.33
CyA + MTX (n, %) 6 (16) 10 (30)
CyA alone (n, %) 4 (11) 2 (6)
Center
A 29 (78) 27 (82) 0.42
B 4 (11) 5 (15)
C 4 (11) 1 (3)
HCT-CI
0 20 (54) 15 (46) 0.091
1-2 17 (46) 14 (42)
> 2 0 (0) 4 (6)
KPS1
90-100 8 (22) 2(6) 0.06
< 80 29 (78) 31 (94)
allo-HCT allogeneic cell transplantation; CMV cytomegalovirus; AML
acute myeloid leukemia; MDS myelodysplastic syndrome; MPN myelo-
proliferative neoplasm; CML chronic myeloid leukemia; ALL acute lym-
phoblastic leukemia; CR complete remission; 2.CR second complete re-
mission; EBMT European Group for Blood and Marrow Transplantation;
aGvHD acute graft-versus-host-disease; ATG anti-thymocyte globulin;
CyA cyclosporine A;MTXmethotrexate;HCT-CI hematopoietic cell trans-
plantation-specific comorbidity index; KPS Karnofsky performance status
1One death before allo-HCT in CyBu ofmultiple organ failure from toxic
megacolon
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by a p value < 0.05. Cumulative incidence function of NRM
and relapse was performed using death of other causes as
competing event, with Fine and Gray to test for differences.
The Kaplan-Meier estimator and the log-rank test were used
for overall survival. Statistical analysis was performed using
the SPSS (version 22; IBM, Chicago, IL, USA) and STATA




Of 114 patients screened, 72 were eligible. Screening failures
were mainly because of preexisting liver abnormalities. A
total of 72 patients were randomized from 2013 to 2017, and
2 were excluded because of delayed identification of
preexisting hepatitis and for donor problems leaving 70
evaluable patients in the trial. Of the 70 evaluable patients,
56 (80%) were treated in center A, 9 (13%) in center B, and
5 (7%) in center C (Table 1). Median age was 47 years and
57% were male. Transplants were from HLA-identical sib-
lings (n = 34, 49%) or from matched unrelated donors (n =
36, 51%). Nine patients had a prior HCT (2 allogeneic and 7
autologous). Median follow-up of surviving patients was
1092 (IQR 730-1364) days. Disease was AML (n = 52,
74%), MDS/MPN (n = 14, 20%), CML (n = 3, 4%), and
ALL (n = 1, 2%). Early disease stage (CR (complete remis-
sion) or first chronic phase) was in 49 (70%) patients, inter-
mediate (second CR or treated upfront) in 11 (16%), and ad-
vanced (no CR) in 10 (14%) patients. A total of 33 patients
were randomized to the standard group (BuCy) and 37 to the
experimental group (CyBu). Distribution of patient, disease,
and transplant characteristics is shown in Table 1 and did not
differ significantly among groups.
Liver toxicity and outcomes
Liver function tests measured as bilirubin, ASAT, ALAT,
GGT, and AP were not different between groups at baseline
(Table 2). The only significant difference was higher levels of
ALAT (median 27 versus 22 IU/L, p = 0.03) in the BuCy as
compared to the CyBu group on day 30. All other liver func-
tion tests did not differ among groups; on day 100, no signif-
icant differences were seen.
Slightly more patients in the BuCy as compared to the
CyBu group had any grade of CTCAE liver toxicity criteria
on day 30 or day 100 (mostly grade 1 toxicity). Even when
combining all CTCAE toxicity criteria, differences did not
reach statistical significance (p = 0.08).
One fatal VOD episode occurred in the BuCy group versus
none with CyBu; the frequency of patients fulfilling at least
one of the predefined VOD criteria, but not being formally
diagnosedwithVOD,was significantly higher in BuCy versus
CyBu groups (17 versus 10 patients; p = 0.05). Median AUC
and Css showed no significant differences between the two
groups: AUC (1126 (630-1595) versus 1006 (582-2477)
μmol/L*min, p = 0.42) and Css (793 (430-1091) versus 689
(398-1693) ng/mL, p = 0.54) in BuCy versus CyBu in 66 of
70 patients. The cumulative incidence of NRM at 4 years was
higher in the BuCy compared to CyBu (27 (15-49)% versus 6
[2–22]%; p = 0.049, Fig. 1a). Cause of death in patients with
NRM did not differ among groups (p = 0.32, see Table 3). The
survival probability at 4 years in the BuCy group tended to be
lower (43 ± 19% versus 63 ± 17%; p = 0.06, Fig. 1b).
In multivariate analysis adjusting for Karnofsky perfor-
mance score and hematopoietic cell transplantation-specific
comorbidity index, RR of death in the BuCy group compared
to CyBu was 2.270 (0.98-5.27), p = 0.056 and corresponding
risk of NRM was 4.76 (1.01-22.42), p = 0.049 confirming
results of univariate analysis.
Median time to engraftment was similar in both groups (15
[14–16] days versus 16 [15–17] days, p = 0.27). The cumula-
tive incidence for aGvHD grade ≥ II and cGvHD was similar
in BuCy (27 (16-48)% and 39 (25-60)%) compared to CyBu
14 ( [6–31]%; and 52 (38-72)% respectively; p = 0.20 for
Table 2 Liver toxicity
CyBu (n = 37) BuCy (n = 33) p value
Day 30
ASAT (median; range) 27 (7-64) 30 (12-882) 0.09
ALAT (median; range) 22 (8-89) 27 (12-676) 0.03
GGT (median; range) 47 (19-261) 67 (22-876) 0.08
AP (median; range) 69 (23-177) 80 (29-325) 0.16
Bilirubin (median; range) 10 (4-53) 10 (3-172) 0.71
Day 100
ASAT (median; range) 29 (17-74) 32 (10-78) 0.45
ALAT (median; range) 31 (12-93) 31 (5-136) 0.76
GGT (median; range) 38 (14-804) 51 (17-364) 0.20
AP (median; range) 68 (37-274) 67 (25-208) 0.96
Bilirubin (median; range) 9 (3-28) 7 (3-19) 0.79
CTCAE grade day 30
Grade 0 (n, %) 19 (51) 12 (36) 0.21
Grade ≥ 1 (n, %) 18 (49) 21 (64)
CTCAE grade day 100
Grade 0 (n, %) 23 (62) 16 (48) 0.25
Grade ≥ 1 (n, %) 14 (38) 17 (52)
CTCAE maximum grade
Grade 0 (n, %) 15 (40) 7 (21) 0.08
Grade > 1 (n, %) 22 (60) 26 (79)
ASAT aspartate amino transferase; ALAT alanine amino transferase; GGT
gamma glutamyl transpeptidase; AP alkaline phosphatase
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aGvHD and p = 0.36 for cGvHD). Relapse at 4 years was
observed in a total of 24 patients (12 in BuCy and 12 in
CyBu). In both groups, the cumulative incidence of relapse
was similar (34 (21-55)% versus 34 (22-55)%; p = 0.79).
Discussion
In this RCT, we compared the order of application of busulfan
and cyclophosphamide for myeloablative conditioning before
allogeneic cell transplantation in patients with hematological
malignancy. Results of this trial support prior hypotheses that
the order of application of Cy and Bu may have an impact on
short- and long-term toxicity and outcome after allo-HCT.
Our study is in line with previous retrospective and animal
studies [6, 7, 16–18], by showing a somewhat lower early
hepatic toxicity and a lower NRM (p = 0.49) at long-term
follow-up after transplantation with CyBu compared to BuCy.
Among two retrospective studies, Cantoni et al. described
increased liver toxicity at day 30, + higher VOD incidence and
higher NRM in BuCy patients compared to CyBu [17].
Rezvani et al. conducted a similar study comparing CyBu to
historic BuCy controls, reporting a lower incidence of VOD
and a decreased day 100 mortality with CyBu in patients with
myelofibrosis. In patients with AML or MDS, NRM differ-
ences were not significant [19]. The study discussed here in-
cluded mainly patients with AML, the study by Rezvani et al.,
mainly MDS/MPN possibly explaining some differences. As
incidence of acute and chronic GvHD and relapse was similar
when comparing the CyBu to the BuCy arm in our study, the
difference in NRM is not explained by the immunological
complication of GvHD or by an impact on malignancy. The
difference in long-term NRM is not fully explained by small
differences in short-term hepatic toxicity.
Busulfan followed by cyclophosphamide (mostly in that
order) is one of the most commonly used myeloablative reg-
imens before allo-HCT; e.g., in patients withAML in the same
time period as this trial (2013-2017), 41% of patients reported
to the EBMT registry had BuCy as their conditioning regimen
(personal communication, M. Labopin). Hassan et al. [8] had
shown in a study that the time interval between busulfan and
cyclophosphamide was of importance for toxicity. In our trial,
this time interval was respected meticulously. In the study by
Hassan et al., busulfan had been administered orally and not
intravenously.
The hepatotoxicity of BuCy regimen is well described
[12–14, 26]; one of the pathomechanism of the hepatotoxicity
of Bu and Cy is the depletion in glutathione levels, which
plays a central role in the metabolism of the toxic metabolites
of Cy in hepatocytes [9, 10]. Glutathione depletion as a mech-
anism of hepatic toxicity had been studied extensively
[27–29]. The precise pathomechanism remains speculative
as we do not have data on glutathione metabolism and other
explanations are possible.
While the incidence of VOD has decreased over the years,
mortality of established VOD remains high [30]. It is known
that inter-individual discrepancy of pharmacokinetics of busul-
fan impacts on toxicity outcomes [31–33]. The introduction of
Table 3 Patient outcomes and
univariate analysis CyBu (n = 37) BuCy (n = 33) p value
Engraftment (mean days, 95% CI) 16 (15-17) 15 (14-16) 0.27
VOD between day 0 and day 30 (n, %) 0 1 (3)
No criterion (n, %) 27 (73) 16 (48) 0.05
1 or more criteria1 (n, %) 10 (27) 17 (52)
aGvHD grade ≥ II (%, 95% CI) 14 (6-31) 27 (16-48) 0.20
cGvHD (at 2 years, %, 95% CI) 52 (38-72) 39 (25-60) 0.36
Cause of death
Relapse (n, %) 9 (75) 10 (56) 0.32
GvHD (n, %) 1 (8) 2 (11)
VOD (n, %) 0 1 (6)
Infection (n, %) 0 4 (22)
Toxicity (n, %) 2 (17) 1 (6)
Long-term outcome
Relapse/progression (at 4 years, %, 95% CI) 34 (22-55) 34 (21-55) 0.79
Non-relapse mortality (at 4 years, %, 95% CI) 6 (2-22) 27 (15-49) 0.049
Survival (at 4 years, %, 95% CI) 63 (46-80) 43 (24-62) 0.06
VOD veno-occlusive disease;HCT hematopoietic cell transplantation;CI confidence interval; aGvHD acute graft-
versus-host disease; cGvHD chronic graft-versus-host disease
1 Including hyperbilirubinemia > 34 mmol/L, painful hepatomegaly, ascites
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busulfan therapeutic drug monitoring between 2000 and 2010
led to a reduction in adverse outcomes regarding liver toxicity,
highlighted by a reduction in the VOD incidence from 15% in
the late 1990s to 3% after 2010 after dose adjustment of bu-
sulfan during this time period [26, 31]. In our trial, the inci-
dence of severe VOD is 1.4% (one case in 70 patients) and this
is comparable to the literature, where incidence of 2-5% has
been described [26, 34]. We have to take into account that
patients with preexisting liver problems were excluded.
Furthermore, when using VOD criteria as defined by Mohty
et al. [35], more patients in the BuCy arm had fulfilled at least
one criterion than the CyBu arm.
Despite the power of a prospective randomized trial, we
acknowledge limitations of this trial: Sample size is limited,
and the clinical trial unit did not allow for randomization of a
larger patient number, given published differences in retro-
spective studies [18]. Screening failure was 39% excluding
patients with preexisting liver abnormalities, thus assuring
the inclusion of patients with normal liver function, best suited
to test the study hypothesis. Patient accrual was low because of
a general tendency to increasingly use reduced intensity regi-
mens. Randomization was not blinded; however, bias in mea-
suring liver function tests or NRM is unlikely. Furthermore,
we saw some heterogeneity based on center’s specific trans-
plant procedures, such as GvHD and other prophylaxis (e.g.,
ATG use to prevent GvHD, heparin use to prevent VOD), and
in diseases of patients randomized.
We found some limited differences in the hepatic toxicity,
although the differences are not large and we do not know if
they are clinically meaningful. Factors other than the
Fig. 1 a Non-relapse mortality
(CyBu in blue, BuCy in red). b
Survival (CyBu in blue, BuCy in
red)
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conditioning regimen may impact liver function tests early
after HCT. Differences in long-term survival and NRM had
not been pre-specified in the study protocol. Causes of death
did not differ significantly between groups. It appears that
infectious death is more frequent in the ByCy group. Of the
4 infectious deaths, one patient had ATG, one had
alemtuzumab, and two had no T cell depletion. Therefore, T
cell depletion does not appear to explain small differences in
infectious mortality.
Conclusions
In conclusion, we demonstrate that order of application of
cyclophosphamide and busulfan may influence outcome
when used in myeloablative conditioning for hematological
malignancy. Additional data need to be generated on pharma-
cology of drugs used in conditioning to achieve safer individ-
ualized chemotherapeutic treatment.
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